Clinical trial
Humanized LL2IGG to Treat Systemic Lupus Erythematosus
NCT00011908 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT00011908 |
|---|---|
| Title | Humanized LL2IGG to Treat Systemic Lupus Erythematosus |
| Official title | A Phase I Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Systemic Lupus Erythematosus |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | hLL2 (Epratuzumab) |
| Enrollment | 20 |
| Start date | Feb 1, 2001 |
| Completion | Jan 1, 2003 |
| First posted | Mar 5, 2001 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: